Stocks · News reference
Piper Sandler analyst Alexander Goldfarb maintains BXP (NYSE:BXP) with a Overweight and lowers the price target from $88 to $72.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Healthpeak Properties (DOC) reported Q3 2026 FFOA of $0.44 per share, beating estimates by 2.3%, with revenues up 16.3% YoY to $820.9 million. The company raised 2026 FFOA guidance to $1.76-$1.78 per share, supported by solid outpatient leasing, improving lab occupancy, and strong senior housing performance from Janus Living. However, operating expenses surged 30% YoY, and the company carries a Zacks Rank #4 (Sell) rating.
Jefferies has updated its price target for BXP, Inc., raising it from $66 to $70.
BXP, Inc. announced its financial results for the third quarter ended September 30, 2026, reporting revenue of $911.4 million and FFO of $1.89 per share.
Filed: 2026-10-27 AccNo: 0001037540-26-000041 Size: 6 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Analysts downgraded BXP, MDXH, AOS, NMRK and LCII, cutting price targets for BXP, AOS, NMRK and LCII.